web analytics
4.7 C
Munich
Tuesday, November 29, 2022

Shareholder Update Sparks TapImmune Inc.(OTCMKTS:TPIV)

TapImmune Inc.(OTCMKTS:TPIV) is making a strong move up after the Company announced an update from CEO Glynn Wilson, Ph.D. on their multiple Phase 2 Trials, over $9 Million in New Funding & NASDAQ up-listing Application.

TPIV originally started moving in anticipation of the ASCO Annual Meeting at the McCormick Place in Chicago which started back on May 29 from lows of $0.121 to highs of $1.71.

TapImmune Inc.(OTCMKTS:TPIV) peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities.

The Company recently announced positive Phase 1 clinical data from its Folate Receptor Alpha trial in triple negative breast and ovarian cancer. This trial demonstrated the experimental therapy was safe, well-tolerated and provided a robust immune response. Data from the Folate Receptor Alpha trial and the HER2Neu Phase 1 trial are very encouraging and a further data release from the Her2neu breast cancer Phase 1 trial is expected shortly. The infusion of capital from the exercise of the series B and C warrants will ensure the Company will complete the planned Phase 2 trial program.

TPIV said they intend to move two of its products into phase 2 clinical trials in 2015 and mentioned that a financing raise will be necessary to continue with its operating plan.

TPIV has an exclusive Licensing Option agreement with Mayo Clinic, Rochester, MN, for clinical development of a breast cancer vaccine technology. The option to license this technology can be exercised after Phase I clinical trials under terms agreed between Mayo Clinic and TapImmune. Mayo Clinic will conduct a Phase I clinical trial in breast cancer patients who have a form of breast cancer that express Her2/neu receptors (also called Her2/neu breast cancer). Dr. Keith Knutson, Ph D. will serve as Principal Investigator.

 To Find out the inside Scoop on TPIV Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

In Phase 1 over 95% of patients in both Her2neu positive breast cancer and in folate receptor alpha positive ovarian cancer demonstrated positive immune responses to TapImmune’s antigens. Success in these trials has provided a strong basis for progression to Phase 2.  “We plan to initiate a Phase 2 clinical trial in triple negative breast cancer in the near future,” said Wilson.

Triple-negative breast cancer is breast cancer that is unresponsive to standard biomarker-targeted or hormonal treatment.  TNBC tumors test negative for the estrogen and progesterone receptors and positive for the HER2 receptor.  Approximately 15-20% of all breast cancer patients are triple negative and there are few treatment options for these patients.  In the United States approximately 40,000 women are diagnosed with TNBC each year and there are many hundreds of thousands of recovered breast cancer patients at high risk of recurrence. This indication and lack of available therapeutics make this drug an ideal candidate for Fast Track and Orphan Drug designations from the FDA and the company will be making those applications along with its Phase 2 FDA filings.

On September 6 TPIV CEO Glynn Wilson, Ph.D. stated We believe we are now funded to execute on the 4 Phase 2 clinical trials for our lead cancer vaccine TPIV 200, two of which have already started treating patients, with two more trials slated to commence enrollment in the coming few quarters. Our second cancer vaccine product, TPIV 110, is currently expected to enter a Phase 2 trial early in 2017.

More updates include: $9.0 Million Equity Raise & Elimination of $29 Million Derivative Liability The $9 million cash influx, combined with the elimination of the derivative liability creates a balance sheet for TapImmune that enabled us to apply for an uplisting of our common stock to the NASDAQ Capital Market. It also provides available cash to execute on the 4 Phase 2 trials of our lead clinical candidate TPIV 200, while also providing funding for the continued advancement of our second clinical candidate TPIV 110, slated to enter Phase 2.

TPIV has opened 8 clinical sites and begun treating patients in a Phase 2 trial of our Folate Receptor Alpha cancer vaccine, TPIV 200, in the treatment of triple negative breast cancer, one of the most difficult to treat cancers representing a clear unmet medical need. A Phase 2 study of TPIV 200 in ovarian cancer patients who are not responsive to platinum has begun enrollment for a 40 patient study.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $34 million market valuation TPIV has $1.4 million in the treasury, no revenues to date and rising short term debt. But this is an exciting story developing in small caps; the Company has been making some huge advancements recently announcing $9 million in new funding & NASDAQ up-listing application. TPIV now has the funding in place for 4 Phase 2 clinical trials for their lead cancer vaccine TPIV 200. We will be updating on TPIV when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with TPIV.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in TPIV either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.